ArticleAIMS neuroscience2026
Association between TNFa rs1800629 and migraine: Case-control study and updated meta-analysis.
Article in AIMS neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a multifactorial disorder influenced by both genetic and environmental factors. In this study, we aimed to explore the association of tumor necrosis factor alpha (TNFa) rs1800629 with migraine susceptibility. A case-control study design was employed to assess this association in individuals of Greek ancestry. Subsequently, a meta-analysis of published studies was conducted, thereby incorporating the findings of the present study to further evaluate the relationship between rs1800629 and a migraine. A total of 123 patients with migraines (44.4 ± 10.3 years, 105 women) and an even number of healthy controls (HC) (58.7 ± 12.0 years, 76 women) were recruited. TNFa rs1800629 was in Hardy-Weinberg equilibrium among the HC (P = 1.00). No association was observed between TNFa rs1800629 and migraines under any genetic model. Additional, subgroup analyses stratified by sex and migraine subtype showed no associations. The meta-analysis, comprised of 14,742 participants with migraines and 46,384 HC, indicated a trend towards a risk-conferring effect of rs1800629 [Odds ratio (OR) = 1.26, 95% confidence interval (95% CI) = (0.97-1.64), P = 0.09]. Subgroup analyses revealed a significant association in individuals of Asian ancestry [OR = 1.64, 95% CI = (1.08-2.48), P = 0.02]. Additionally, the over-dominant model was related to migraines with aura [OR = 1.21, 95% CI = (1.08-1.35), P = 0.001]. Subgroup analyses for men and women, as well as for migraines without aura, were insignificant. This case-control study provides evidence that the TNFa rs1800629 polymorphism is not associated with migraine susceptibility in the Greek population. The updated meta-analysis showed that rs1800629 increases migraine risk in individuals of Asian ancestry. These findings support a population-specific genetic effect. Finally, the observed association with migraine with aura under the over-dominant model may indicate a heterozygote-driven effect. Given the extremely low frequency of homozygosity for the minor allele, this result should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.